Asset Details
Do you wish to reserve the book?
Update on Management of Pediatric Renal Neoplasms
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Update on Management of Pediatric Renal Neoplasms
Do you wish to request the book?
Update on Management of Pediatric Renal Neoplasms
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Update on Management of Pediatric Renal Neoplasms
2023
Overview
Purpose of Review
The treatment of pediatric renal tumors is nuanced and complex. This review highlights these nuances and aims to prepare the surgeon for treating these complex patients.
Recent Findings
Cooperative group study has improved survival for several pediatric renal tumors significantly, namely, Wilms tumor and clear cell sarcoma. There are several more rare tumors however, which have not achieved the same level of success and still require more study to find the optimal treatment regimen to achieve excellent overall survival. These tumors include rhabdoid tumor and renal medullary carcinoma. Several COG Wilms tumor protocols have recently closed and new ones are set to release soon. It is anticipated that these studies will continue to shift focus to minimizing adverse events/late effects by potentially eliminating or reducing chemotherapeutic exposures while maintaining excellent overall survival. Specifically, new discovery of molecular markers in Wilms tumor will play a significant role with respect to risk stratification. Already, loss of heterozygosity at both 1p and 16q prompts treatment intensification as they are associated with decreased survival. However, gain of 1q, independent of 1p/16q mutations, seems to be more common and even more tightly associated with poor outcomes, which will likely be a key factor involved with adjuvant therapy considerations.
Summary
New treatment protocols for Wilms tumor are forthcoming and will include more molecular markers for risk stratification. Other COG studies on more rare renal tumors are underway to further improve survival for patients with these malignancies.
Publisher
Springer International Publishing
